Silje Watterdal Syversen (Silje W Syversen)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 12

Top Topics

Coronavirus Disease

Ulcerative Colitis

Prognostic Factors

Ejection Fraction

Top Venues

Arthritis & rheumatology (Hoboken, N.J.)

Rheumatology international

Journal of internal medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Hilde S Ørbo, Kristin Hammersbøen Bjørlykke, Joseph Sexton, Ingrid Jyssum, Anne Therese Tveter, Ingrid Egeland Christensen, Siri Mjaaland, Tore K Kvien, Gunnveig Grødeland, Grete B Kro, Jørgen Jahnsen, Espen A Haavardsholm, Ludvig A Munthe, Sella Aarrestad Provan, John T Vaage, Guro Løvik Goll, Kristin Kaasen Jørgensen, Silje Watterdal Syversen
Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study. RMD open 10 (2) (2024)
Hilde S Ørbo, Kristin Hammersbøen Bjørlykke, Joseph Sexton, Ingrid Jyssum, Anne Therese Tveter, Ingrid Egeland Christensen, Siri Mjaaland, Tore K Kvien, Gunnveig Grødeland, Grete B Kro, Jørgen Jahnsen, Espen A Haavardsholm, Ludvig A Munthe, Sella Aarrestad Provan, John T Vaage, Guro Løvik Goll, Kristin Kaasen Jørgensen, Silje Watterdal Syversen
Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study. RMD open 10 (2) (2024)
Hilde S Ørbo, Kristin Hammersbøen Bjørlykke, Joseph Sexton, Ingrid Jyssum, Anne Therese Tveter, Ingrid Egeland Christensen, Siri Mjaaland, Tore K Kvien, Gunnveig Grødeland, Grete B Kro, Jørgen Jahnsen, Espen A Haavardsholm, Ludvig A Munthe, Sella Aarrestad Provan, John T Vaage, Guro Løvik Goll, Kristin Kaasen Jørgensen, Silje Watterdal Syversen
Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study. RMD open 10 (2) (2024)
Hilde S Ørbo, Kristin Hammersbøen Bjørlykke, Joseph Sexton, Ingrid Jyssum, Anne Therese Tveter, Ingrid Egeland Christensen, Siri Mjaaland, Tore K Kvien, Gunnveig Grødeland, Grete B Kro, Jørgen Jahnsen, Espen A Haavardsholm, Ludvig A Munthe, Sella Aarrestad Provan, John T Vaage, Guro Løvik Goll, Kristin Kaasen Jørgensen, Silje Watterdal Syversen
Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study. RMD open 10 (2) (2024)
Hilde S Ørbo, Kristin Hammersbøen Bjørlykke, Joseph Sexton, Ingrid Jyssum, Anne Therese Tveter, Ingrid Egeland Christensen, Siri Mjaaland, Tore K Kvien, Gunnveig Grødeland, Grete B Kro, Jørgen Jahnsen, Espen A Haavardsholm, Ludvig A Munthe, Sella Aarrestad Provan, John T Vaage, Guro Løvik Goll, Kristin Kaasen Jørgensen, Silje Watterdal Syversen
Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study. RMD open 10 (2) (2024)
Silje Watterdal Syversen, Johanna E Gehin, Guro Løvik Goll, Nils Bolstad, Espen A Haavardsholm, Siri Lillegraven
Therapeutic Drug Monitoring: A Tool to Optimize Treatment of Inflammatory Joint Diseases. Arthritis & rheumatology (Hoboken, N.J.) (2023)
Marthe Kirkesaether Brun, Kristin Hammersbøen Bjørlykke, Marte K Viken, Grethe-Elisabeth Stenvik, Rolf Anton Klaasen, Johanna Elin Gehin, David John Warren, Joseph Sexton, Øystein Sandanger, Tore K Kvien, Cato Mørk, Espen A Haavardsholm, Jørgen Jahnsen, Guro Løvik Goll, Benedicte A Lie, Nils Bolstad, Kristin Kaasen Jørgensen, Silje Watterdal Syversen
HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases. Journal of internal medicine (2023)
Silje Watterdal Syversen, Ingrid Jyssum, Anne Therese Tveter, Joe Sexton, Ingrid Egeland Christensen, Trung T Tran, Kristin Hammersbøen Bjørlykke, Siri Mjaaland, David J Warren, Tore K Kvien, Adity Chopra, Grete Birkeland Kro, Jorgen Jahnsen, Ludvig A Munthe, Espen A Haavardsholm, Gunnveig Grødeland, John Torgils Vaage, Sella Aarrestad Provan, Kristin Kaasen Jørgensen, Guro Løvik Goll
Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy. RMD open 8 (2) (2022)
Johanna Elin Gehin, Guro Løvik Goll, Marthe Kirkesaether Brun, Meghna Jani, Nils Bolstad, Silje Watterdal Syversen
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 36 (6) (2022)
Silje Watterdal Syversen, Ingrid Jyssum, Anne Therese Tveter, Trung T Tran, Joseph Sexton, Sella Aarrestad Provan, Siri Mjaaland, David J Warren, Tore K Kvien, Gunnveig Grødeland, Lise S H Nissen-Meyer, Petr Ricanek, Adity Chopra, Ane Marie Anderson, Grete B Kro, Jørgen Jahnsen, Ludvig A Munthe, Espen A Haavardsholm, John T Vaage, Fridtjof Lund-Johansen, Kristin Kaasen Jørgensen, Guro Løvik Goll
Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy. Arthritis & rheumatology (Hoboken, N.J.) 74 (8) (2022)
Johanna Elin Gehin, Rolf Anton Klaasen, Ellen S Norli, David J Warren, Silje Watterdal Syversen, Guro Løvik Goll, Trine Bjøro, Tore K Kvien, Maria D Mjaavatten, Nils Bolstad
Rheumatoid factor and falsely elevated results in commercial immunoassays: data from an early arthritis cohort. Rheumatology international 41 (9) (2021)
Silje Watterdal Syversen, Guro L Goll, Kristin K Jørgensen, Inge C Olsen, Øystein Sandanger, Johanna E Gehin, David J Warren, Joseph Sexton, Cato Mørk, Jørgen Jahnsen, Tore K Kvien, Nils Bolstad, Espen A Haavardsholm
Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study). Trials 21 (1) (2020)